With Capital Scarce, Charities Emerge As A Stronger Force On Start-Up Scene
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Disease charities are traditionally big funders of basic research. But those foundations are increasingly spawning specialized funds aimed at helping start-ups drive their candidates into later stages of development, where they might represent more attractive investment opportunities for pharmaceutical partners.
You may also be interested in...
Deals Of The Week Searches For Meaning In Deal Break-Ups
Amid a dearth of private-sector deals, we review some of this year’s break-ups, take a closer look at the Leukemia & Lymphoma Society’s deal-making strategy and highlight two deals from the U.K.’s Cancer Research Technology, as well as a licensing pact between Adimab and Alector.
Lpath, OptoSonics First To Win New Bridge Grants From NCI’s SBIR Center
The $3 million awards are designed to help companies attract support for the dicey period of transition from preclinical to Phase I.
Lpath, OptoSonics First To Win New Bridge Grants From NCI’s SBIR Center
The $3 million awards are designed to help companies attract support for the dicey period of transition from preclinical to Phase I.